Webinar: HEOR Evidence for Emergent Infectious Diseases

Share on: 
September 16, 2021

Generating and communicating evidence in COVID-19 treatment and vaccine development

Although COVID-19-related disruptions to the pharmaceutical supply chain and to clinical trials created short-term negative impacts for the pharma industry, it also introduced substantial growth opportunities. While companies race to be at the forefront of vaccine and treatment development, current strategies for evidence generation and communication of unmet need and product value have to be developed in the context of a rapidly-evolving​ disease landscape. 

As we return to standard reimbursement processes and evidence requirements, we will continue to face challenges from a continually changing environment. 

In this one-hour webinar, we’ll look at the opportunities and challenges that exist when creating HEOR materials in a dynamic setting and outline a set of best practices for developing evidence-based communication materials for emergent infectious diseases. 

What you will learn: 

  • Overview of vaccine and drug development 
  • Key challenges for developing robust literature reviews, dossiers, and economic models 
  • Best practices in emergent diseases 


Shahnaz Khan, MPH 
Executive Director, Market Access and Outcomes Strategy 

Anne Heyes, MBA 
Vice President, Head Market Access and Outcomes Strategy, Europe 

Kati Copley-Merriman, MBA 
Vice President, Market Access and Outcomes Strategy 

Michele Wilson, MSPH 
Senior Director, Health Economics

Related Services:
Conference participants: